Oral GLP-1 for Weight Loss

What is an oral GLP-1?

An oral GLP-1 is a daily weight loss pill that copies the effects of a hormone your gut already makes. The hormone is glucagon-like peptide-1, usually shortened to GLP-1. Your gut releases GLP-1 after a meal to tell your brain you have had enough. It also slows how fast your stomach empties. 

Medicines that mimic these effects are known as glucagon like peptide-1 (GLP-1) receptor agonists.The result of taking this medication is that you stay feeling full for longer than normal. 

Most people notice their appetite reduce before seeing any change on the scales or in the fit of their clothes. These medicines keep the natural signal from your body’s hormones going for far longer. The urge to eat fades, and cravings quieten across the day — you feel fuller, for longer. The steady, all-day slowing of your stomach is also why you might feel queasy for the first few weeks, while your body adjusts.

GLP-1 medications also help control blood sugar and were developed as a type 2 diabetes treatment first. That same GLP-1 hormone tells your body to release insulin after you eat. It also reduces release of glucagon, a hormone that tells the liver to release stored sugar into the blood. Their use for weight loss came later.

Wegovy and Mounjaro are weekly injections that work through the same pathway and have been available for some time. The newer oral GLP-1s for weight loss are generating interest for a simple reason. They offer similar appetite control as the injections, without the needles.

The Wegovy pill has been approved for use in the UK. Foundayo, however, is still waiting for release.

How do oral GLP-1s compare with injections?

Oral GLP-1 medicines and weight loss injections mimic the same hormone. What changes is the format. Injections like Wegovy and Mounjaro are injected once a week. Both oral Wegovy and Foundayo deliver appetite control and weight loss support in a daily tablet.

How oral GLP-1s work to produce weight loss does not differ between the Wegovy pill and Foundayo. What differs is how your body absorbs each one, and that is what sets their dosing rules apart. Those rules separate the two oral options more than anything else.

Semaglutide is a peptide (small protein), and the stomach breaks proteins down fast. Less than 1% of each dose reaches your blood. That is why the Wegovy tablet needs strict fasting rules and a higher dose when compared to the injection.

Foundayo works differently to get around that problem. Orforglipron is a small molecule, not a protein. It survives digestion, and your body absorbs around 79% of each dose. Its reliable absorption is why Foundayo carries no food or water rules and no waiting before breakfast.

With both tablets, you begin on a small dose and increase it in stages over the first few months. This keeps early side effects milder. With our service, you stay on each dose for at least 30 days, and decide when you feel ready to move up. Not everyone needs to reach the highest dose to see results.

Trial results put oral Wegovy, Foundayo and the Wegovy injection in broadly the same range for weight loss. For most people, the biggest difference is how each treatment fits into daily life rather than the amount of weight loss.

Treatment	Average weight loss in trials	How you take it	UK status
Oral Wegovy (oral semaglutide 25 mg)	About 13.6% over 64 weeks	Once daily, on an empty stomach with a small sip of water (maximum 120mL). Then wait 30 minutes before taking anything else.	MHRA-approved
Foundayo (orforglipron)	About 11% at the top dose over 72 weeks	Once daily, at any time of day. With or without food	Not yet MHRA-approved
Wegovy injection (semaglutide 2.4 mg)	About 15% over 68 weeks	Once weekly injection.	MHRA-approved and available

People often assume a pill must be much weaker than an injection. But clinical trial results show the difference in effectiveness between oral Wegovy and the injection is smaller than many expect. The numbers do come from separate studies, so it’s important to treat them as rough guides and not a like-for-like score.

Is an oral GLP-1 easier to live with than injections?

For many people, yes. The thought of injecting every week is off-putting, and a daily tablet removes that barrier for them. People who are looking to start weight loss treatment look at oral GLP-1 as a solution for needle aversion. 

A pill also travels more easily than a pen. You don’t need to keep the medication cold, and no fixed injection day to plan around. 

The choice is not only about needles and storage. Plenty of people do not mind the jabs and find a weekly schedule easier to keep than a daily one. Remembering 365 doses a year can be more of a challenge than remembering 52. The best treatment for you will be the one you can realistically stick to, because consistency brings the best outcomes.

Results build gradually over a number of months. Weight loss usually takes time and tends to happen after a few dose increases, not right away. The main things to focus on are: staying consistent with your dosing, making small healthy changes to your diet, and being more active. Small, steady changes add up over time. 

If a daily GLP-1 pill for weight loss sounds like a better fit than injections, speak to us. We can check which option would be most suitable for you.

Which oral GLP-1s are available for weight loss in the UK?

As of June 2026, the Wegovy pill has been approved for use in the UK. Foundayo is still awaiting approval from the Medicines and Healthcare products Regulatory Agency, or MHRA. A third oral GLP-1, Rybelsus, already sits on UK shelves, though it is only licensed for treating type 2 diabetes.

Oral Wegovy is the tablet form of semaglutide, the same medicine as the Wegovy injection. 

Foundayo (orforglipron) is the newer option, and the first non-peptide GLP-1 pill approved anywhere in the world. The US regulator, the Food and Drug Administration (FDA), approved it in April 2026. It awaits MHRA review and so is not yet available here in the UK.

Rybelsus already exists in the UK, but only as a treatment for type 2 diabetes. Like Wegovy, it is an oral semaglutide tablet at lower doses. Rybelsus has no weight-loss licence, so we do not prescribe it for that.

For now, anyone weighing up which oral GLP-1s are available in the UK need to know which ones are currently available, and which are waiting on MHRA approval. For available oral GLP-1s, UK patients are limited to the Wegovy pill for weight loss. 

MHRA approval is only the first gate. For NHS access, a second step must happen. The National Institute for Health and Care Excellence (NICE) will need to decide whether the treatment is good value for NHS funding.

This usually follows months later. Oral GLP-1s will most likely be available via private prescription before it will be available on the NHS. 

Who can take an oral GLP-1?

Oral GLP-1 treatments are for adults with obesity. Most adults qualify for oral GLP-1 treatment at a body mass index (BMI) of 30 or above. People with a BMI of 27 and above can also qualify, alongside a weight-related condition. Examples include type 2 diabetes, high blood pressure, sleep apnoea or raised cholesterol. 

NICE sets lower BMI thresholds for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. This is because weight-related risks can develop earlier in patients from these groups.

GLP-1s treat obesity and should not be used for cosmetic weight reduction. A healthcare professional checks your BMI and medical history before prescribing anything.

Anyone pregnant or breastfeeding should not take a GLP-1. GLP-1 treatments are not suitable for anyone with a personal or family history of medullary thyroid cancer or the inherited condition MEN2. The same applies if you have previously had pancreatitis. An oral GLP-1 always works best alongside changes to diet and exercising habits that support weight management long term.

Because our consultation is online, the assessment questions do the same job a face-to-face clinic visit normally would. It’s important to answer all the questions as fully and honestly as you can, so we can make sure the treatment is safe and right for you. 

A full check of who oral GLP-1 is for sits inside every consultation. Our prescribers review your answers before they approve your prescription. You lead on choosing your treatment, and we confirm it is safe for you.

When should I see a doctor?

Most side effects of oral GLP-1 treatments are mild, and they ease as your body gets used to the medication. The most common are gastrointestinal side effects: nausea, vomiting, diarrhoea and constipation. These usually appear in the first few weeks of starting treatment and after dose increases and tend to fade on their own. If they drag on, though, or you have a question about your dose, our clinical team can help.

Some side effects are more serious and need a same-day check instead. Contact your GP or call NHS 111 if you notice:

• a lump in your neck, a hoarse voice or trouble swallowing. These can be signs that your thyroid needs checking
• signs of a gallbladder problem, like yellow skin or severe pain in the upper-right of your tummy
• vomiting has not stopped for more than six hours, and you cannot keep fluids down
• Any changes to your vision

Stop your oral GLP-1 and call 999 or go to A&E if you notice any of these:

• severe tummy pain that spreads through to your back, a possible sign of pancreatitis
• a serious allergic reaction affecting your breathing, lips or throat
• If you are not able to keep down water or fluids

Frequently asked questions

Will I put the weight back on if I stop taking an oral GLP-1?

Weight regain is common if you stop. In the STEP 1 trial extension, people stopped the semaglutide injection. Within a year, they regained about two-thirds of their lost weight.

A similar pattern is likely with oral GLP-1s. For most people, holding body weight off means staying on treatment or having a firm plan for their maintenance phase.

Can I switch between Wegovy injections and an oral GLP-1?

Now that the MHRA has approved the Wegovy pill for the UK, switching from Wegovy injections to the Wegovy pill should be straightforward.

Foundayo is a different molecule, but switching protocols do exist. Change only with your prescriber’s guidance, and never take two GLP-1 medicines at once.

Oral Wegovy or Foundayo: which should I choose?

In trials, oral Wegovy produced slightly more weight loss than Foundayo, around 13.6% against 11%. But no trial compared the two directly.

Foundayo wins on convenience, with no food or water rules and no fixed timing. Oral Wegovy needs an empty stomach and a careful morning routine.

Can I take an oral GLP-1 alongside my other medicines?

Usually, but the timing can matter. Oral semaglutide needs an empty stomach. You take it first with no more than 120mls of water. Leave about 30 minutes before other tablets, food or drink. 

Foundayo does not tie you to that window.

One firm rule applies to all of them: never combine an oral GLP-1 with another GLP-1 medicine. Tell us about everything you take, including anything bought over-the-counter. We will check for any interactions or potential safety issues.

Why isn’t Rybelsus prescribed for weight loss if it contains semaglutide?

Rybelsus and the Wegovy pill both contain semaglutide, but at different doses and for different jobs. Rybelsus is licensed for type 2 diabetes at lower doses of up to 9 mg a day in the round tablet form. That dose suits blood sugar control. The weight loss version uses a maximum of 25 mg, trialled and licensed specifically for weight management.

What should I do if I miss a dose?

Skip the missed dose and resume at your usual time the next day. Never take two doses together to catch up. If you have missed several days, check with our clinical team before restarting to reduce the risk of side effects re-emerging.

Key takeaways

• Oral GLP-1 receptor agonists put the appetite-lowering effect of the injections into a daily tablet.
• The Wegovy pill has been approved for a UK release by the MHRA. Foundayo has US approval but has not been approved by the MHRA yet.
• If needles are your main barrier, a daily pill could help you through. However, it will require a different schedule compared to injections.

References

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4), New England Journal of Medicine, 2025 [Accessed 1 June 2026].

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), New England Journal of Medicine, 2025 [Accessed 1 June 2026].

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine, 2021 [Accessed 1 June 2026].

Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide (STEP 1 Trial Extension), Diabetes, Obesity and Metabolism, 2022 [Accessed 1 June 2026].

Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants, Clinical Pharmacology in Drug Development, 2026 [Accessed 1 June 2026].

Current Understanding of SNAC as an Absorption Enhancer: The Oral Semaglutide Experience, Clinical Diabetes, 2024 [Accessed 1 June 2026].

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials, Clinical Pharmacokinetics, 2021 [Accessed 1 June 2026].

Wegovy (semaglutide) Prescribing Information, US Food and Drug Administration, 2025 [Accessed 1 June 2026].

Overweight and obesity management (NG246), National Institute for Health and Care Excellence, 2025 [Accessed 1 June 2026].

FDA approves Lilly’s Foundayo (orforglipron), Eli Lilly and Company, 2026 [Accessed 1 June 2026].

Rybelsus 9 mg Tablet — Summary of Product Characteristics, electronic medicines compendium (emc), 2026 [Accessed 1 June 2026].

Authorship